Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited

NEW YORK, Jan. 7 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited (UNI-ASX). The full 72-page report can be found at and

Unilife Medical Solutions Limited ("Unilife" or "the Company") develops and supplies innovative safety medical devices to healthcare and pharmaceutical markets. Specifically, the Company is focused on targeting pharmaceutical markets for prefilled safety syringes; healthcare markets that mandate the use of sharps safety devices to prevent needlestick injuries; and the U.S. medical device contract manufacturing market. Unilife has developed a patent-protected portfolio of safety syringes, with product lines including the Unilife Ready-to-Fill Syringe ([RTFS] hereafter referred to as the Unilife Prefilled Syringe), the Unitract(TM) 1mL Insulin and Safe Syringes, and the Unitract(TM) Clinical Range.

The key distinctive feature in all of Unilife's safety syringes is that the operator may control the speed of automatic needle retraction within a fully integrated safety syringe. This novel combination of safety features, which Unilife does not believe is available with any other technology on the market today, can virtually eliminate the risk of acquiring bloodborne infections, such as the human immunodeficiency virus (HIV) or hepatitis C, via needlestick injuries or aerosol (blood splatter).

In July 2008, sanofi-aventis SA (SNY-NYSE) -- the world's fourth largest pharmaceutical group and largest purchaser of prefilled syringes -- signed an Exclusive Agreement with Unilife, under which sanofi-aventis paid $13.9 million (euro 10 million) for the right to purchase the Unilife Prefilled Syringe for five years. Sanofi-aventis is also financing Unilife's three-year industrialization program for the Unilife Prefilled Syringe, which could have a total value of up to $23.6 million (euro 17 million). The Company believes that this alliance validates the strength of its proprietary technology and its competency in the development and operation of automated assembly systems. Upon the expected signing of two additional agreements with sanofi-aventis in the next 18 months, Unilife maintains a solid cash position and projects profitable operations moving forward.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of forty-two thousand five hundred U.S. dollars and five hundred thousand Options/Warrants to purchase Unilife stock for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the Australian Securities Exchange (ASX).

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.

SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Crystallography reveals the 3-D structure of mammalian sperm receptor
2. Asia Wellness Cruise Offers Crystal Guests Peace of Mind, Body & Spirit
3. Crystalens HD(TM) Receives FDA Approval
4. Success for Crystal Meth Drug Addict on YouTube
5. Steve and Paula Mae Schwartz Honored With Publicity Club of New Englands Crystal Bell Award
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Advaxis, Inc.
8. Measurement technique probes surface structure of gold nanocrystals
9. Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women
10. Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages
11. A New Year, A New Opportunity: Metropolitan Community Church Leaders Urge Faith Leaders to Address HIV and Crystal Meth Use Among LGBT Youth
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: